Research programme: Src kinase inhibitor - Keryx

Drug Profile

Research programme: Src kinase inhibitor - Keryx

Alternative Names: Src kinase inhibitor research programme - Keryx

Latest Information Update: 04 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Keryx Biopharmaceuticals
  • Class
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 04 Dec 2006 Discontinued - Preclinical for Prostate cancer in Israel (unspecified route)
  • 09 Nov 1999 Preclinical development for Prostate cancer in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top